Jul 2026· Advancement of science· 0 citations· 71 references
Medicine
TL;DR
A xenogeneic‐free strategy that develops the hepatic cellular repertoire with interdigitating vasculature using an air‐liquid interface approach provides a robust, xenogeneic‐free platform for disease modeling, evaluating drug responses, and exploring regenerative therapies.
Abstract
ABSTRACT Organoids derived from human induced pluripotent stem cells (iPSCs) serve as advanced multicellular models for studying human organ development and disease. Recent liver organoid platforms focus on achieving multicellular organization while minimizing reliance on xenogeneic extracellular matrices to support future clinical translation. Building on these advances, this study establishes a xenogeneic‐free strategy that develops the hepatic cellular repertoire with interdigitating vasculature using an air‐liquid interface approach, generating highly vascularized, multicellular, and functional liver organoids from de‐identified control and metabolic dysfunction‐associated steatohepatitis (MASH) donor‐derived iPSCs. Phenotypic and functional characterization confirms the presence of hepatocytes, cholangiocytes, stellate cells, sinusoidal endothelial cells, and Kupffer‐like cells. These organoids demonstrate the capacity to model steatohepatitis following free‐fatty acid exposure and predict acetaminophen‐induced drug toxicity. Organoids derived from MASH‐donors exhibit increased susceptibility to steatosis, inflammation, fibrosis, and acetaminophen‐induced toxicity. Lipidomic profiling reveals that MASH phenotype in organoids induces global lipidomic shifts that closely resemble those observed in MASH liver biopsies. Further post‐transplantation into mice, the organoids retain hepatic cell repertoire, establish functional anastomoses with host vasculature, display intraluminal erythrocytes, and secrete human‐specific albumin, validating their translational potential. This approach provides a robust, xenogeneic‐free platform for disease modeling, evaluating drug responses, and exploring regenerative therapies.
This review systematically summarises current fabrication strategies, disease‐modelling utilities and regenerative potentials of liver organoids, alongside the major challenges and future directions.
Tiepeng Wang, Xiaotian Qu, Jinhong Si et al.· Cell Proliferation· 0 citations
It is suggested that HSC heterogeneity, whether iPSC-derived or donor-derived, is an important factor in fibrotic output and response variability in human liver organoid models and should be considered in model design, interpretation and comparison between studies.
Yu-Wei Yang, Mina Kazemzadeh Dastjerd, Ayla J. Smout et al.· Cells· 0 citations
Several genetic variants have been identified that impact outcomes in patients with metabolic dysfunction-associated steatohepatitis (MASH), but cellular platforms to identify molecular targets for treatment remain scarce. This study aims to employ a polygenic risk score for hepatic fat content (PRS-HFC) in a human-bas...
A. Gatzios, M. Stinckens, A. Verhoeven et al.· Life Science· 0 citations
Vascularized liver organoids are developed by integrating human induced pluripotent stem cell (iPSC)–derived hepatoblasts and endothelial cells into decellularized scaffolds functionalized with an anti-CD31 aptamer–based vascular coating agent (VCA) to establish a comprehensive framework for generating physiologically...
Da-Hyun Kim, Yongju Lee, Min-Ji Kim et al.· Science Advances· 1 citation
This Review summarizes recent technological progress, discusses strategies to improve regulatory fidelity and functional benchmarking, and outlines future directions toward developing liver organoids as more reliable platforms for disease modeling and precision hepatology.
Xi Xu, Caimeng Zhuang, Yuchen Liu et al.· The Innovation Drug Discover...· 0 citations
A cryopreservable and scalable workflow is developed to generate hiPSC-derived hepatic organoids that can be directly matured to either static HLOs or LoC systems, enabling matched comparison of both platforms and establishing a robust hiPSC-derived LoC platform.
Isabel Tamargo-Rubio, T. Krempel, Victoria Palasantzas et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.